Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacodynamic Biomarkers for Emerging LRRK2 Therapeutics

6 Aug 2020

Abstract excerpt

gene as important components of Parkinson's disease (PD) pathobiology. Biochemical and emergent biomarker studies have coalesced around LRRK2 hyperactivation in disease. Therapeutics that diminish LRRK2 activity, either with small molecule kinase inhibitors or anti-sense oligonucleotides, have recently advanced to the clinic. Historically, there have been few successes in the development of therapies that might...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Parkinson's Disease Mechanisms and Treatments
Share to Plant biochemistry and biosynthesis
Share to Plant Gene Expression Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32903744
DOI: 10.3389/fnins.2020.00807

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacodynamic Biomarkers for Emerging LRRK2 TherapeuticsPMID 32903744Read ↗

The Current State-of-the Art of LRRK2-Based Biomarker Assay Development in Parkinson’s DiseaseSemantic proximity Read ↗

Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson diseaseSemantic proximity Read ↗

An Assessment of LRRK2 Serine 935 Phosphorylation in Human Peripheral Blood Mononuclear Cells in Idiopathic Parkinson’s Disease and G2019S LRRK2 CohortsSemantic proximity Read ↗

Single molecule array measures of LRRK2 kinase activity in serum link Parkinson’s disease severity to peripheral inflammationSemantic proximity Read ↗

Mitoxantrone Hydrochloride Targets APP and LRRK2 to Improve Neurodegeneration in Parkinson’s ModelsSemantic proximity Read ↗

Leucine-rich repeat kinase 2 (LRRK2): an update on the potential therapeutic target for Parkinson’s diseaseSemantic proximity Read ↗

Development of mutation-selective LRRK2 kinase inhibitors as precision medicine for Parkinson's disease and other diseases for which carriers are at increased riskSemantic proximity Read ↗

Precision Stratification: Kinase Assay in Asian <i>LRRK2</i> Risk Carriers and Idiopathic Parkinson DiseaseSemantic proximity Read ↗

Understanding LRRK2 kinase activity in preclinical models and human subjects through quantitative analysis of LRRK2 and pRab10Semantic proximity Read ↗

Understanding LRRK2 kinase activity in preclinical models and human subjects through quantitative analysis of LRRK2 and pT73 Rab10Semantic proximity Read ↗

Recent Developments in LRRK2-Targeted Therapy for Parkinson’s DiseaseSemantic proximity Read ↗

Proteome Wide Association Studies of LRRK2 variants identify novel causal and druggable for Parkinson’s diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.